[Topoisomerase I inhibitor (irinotecan hydrochloride)].
Inoue
Shoichi
S
Department of Environmental Medicine and Informatics, Hokkaido University Graduate School of Environmental Earth Science.
Hassan
Mohamed Kamel
MK
Kanetoshi
Akio
A
D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood* / Q000493:pharmacokinetics; D015415:Biomarkers / Q000097:blood; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000097:blood* / Q000493:pharmacokinetics; D002851:Chromatography, High Pressure Liquid; D004347:Drug Interactions; D016903:Drug Monitoring / Q000379:methods*; D006801:Humans; D007150:Immunohistochemistry; D000077146:Irinotecan; D011355:Prodrugs / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D012016:Reference Values
D000972:Antineoplastic Agents, Phytogenic; D015415:Biomarkers; D011355:Prodrugs; D000077146:Irinotecan; D002166:Camptothecin